This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A discussion on the chances of approval and market potential for KemPharm's (KMPH) KP201/Apadaz in short-term management of acute pain

Ticker(s): KMPH

Who's the expert?

The expert will be someone with significant experience in acute pain management and a deep knowledge of other available hydrocodone combination products such as Vicodin, Norco and Lortab.

Interview Questions
Q1.

Can you describe your experience in acute pain management and your knowledge of the other hydrocodone combination products, Vicodin, Norco and Lortab? 

Added By: pjloria
Q2.

Can you highlight the differences in labeling, data, and profiles of these drugs?

Added By: pjloria
Q3.

Given the current data, what are your thoughts and concerns regarding KP201?

Added By: pjloria
Q4.

Do you agree that the KP201 formulation is abuse-deterrent?

Added By: pjloria
Q5.

If KP201 is abuse-deterrent, will doctors prescribe it more than Vicodin, Norco and Lortab? 

Added By: pjloria
Q6.

What percentage of new patients do you think will use KP201 if it is approved? What percentage will remain on Vicodin, Norco and Lortab? 

Added By: pjloria
Q7.

Given the current data, what chance do you think KP201 has of being approved by the FDA?

Added By: pjloria

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.